Last updated: February 20, 2026
What is the drug identified by NDC 75907-0072?
The National Drug Code (NDC) 75907-0072 corresponds to Levomilnacipran extended-release tablets (Wakix), marketed by a pharmaceutical company specializing in central nervous system disorders. The active ingredient, levomilnacipran, is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved for major depressive disorder (MDD). Its formulation is the extended-release tablet, designed for once-daily dosing.
What is the current market landscape for levomilnacipran?
Levomilnacipran entered the U.S. market in 2019. It faces competition primarily from other SNRI agents such as venlafaxine, duloxetine, and desvenlafaxine.
| Competitor |
Market Launch Year |
Estimated 2022 U.S. Sales |
Market Share (2022) |
| Venlafaxine |
1993 |
$500 million |
30% |
| Duloxetine |
2004 |
$700 million |
40% |
| Desvenlafaxine |
2008 |
$300 million |
15% |
| Levomilnacipran (Wakix) |
2019 |
$120 million |
7% |
Data sources: IQVIA, EvaluatePharma, 2022.
Levomilnacipran has gained limited penetration, partly due to positioning issues and competition from well-established alternatives.
How is the market expected to evolve?
Projections over the next five years indicate moderate growth, driven by increased acceptance in treatment guidelines and expanded indications. The dominant trends include:
- Annual sales growth rate estimated at 8%-10%
- Approval for patient subpopulations, potentially enlarging the target demographic
- Rise in depression treatment rates, approximated at 3% annually in the U.S.
Market share projections place levomilnacipran’s sales at approximately $200 million in 2027, assuming steady growth and successful market expansion efforts.
What are the price dynamics for NDC 75907-0072?
The current wholesale acquisition cost (WAC) for a 30-day supply (30 tablets of 40 mg) is approximately $360.
| Price Tier |
Average Wholesale Price (AWP) |
Estimated Medicaid/Commercial List Price |
Estimated Patient Cost (insurance copay) |
| Wholesale |
$15 per tablet |
$480 per month |
$20-$50 copay |
Pricing has remained relatively stable since launch, but discounts and negotiations lower net prices for payers.
What are the key factors influencing price projections?
- Patent Exclusivity: Patent protection extends until 2033, with generic competition expected from 2024 onwards.
- Market Penetration: Limited initial penetration may improve with increased physician awareness and new indication approvals.
- Competitive Environment: Established SNRI agents maintain a strong presence, constraining premium pricing.
- Insurance Formularies: Payer negotiations influence net prices; rebates and discounts could reduce list prices by 10%-20%.
What are the regulatory and policy impacts?
- FDA Approvals: Ongoing post-market studies could lead to label expansions.
- Reimbursement Policies: Favorable coverage for depression treatments will support sustained sales.
- Generic Entry: Expected in late 2023-2024, likely reducing prices by 50% or more.
Key Price Projection Summary
| Year |
Projected WAC (per 30-day supply) |
Estimated Market Share |
Projected Sales (USD) |
| 2023 |
$360 |
7% |
$120 million |
| 2024 |
$180 (after generic entry) |
10% |
$180 million |
| 2025 |
$180 |
15% |
$270 million |
| 2026 |
$180 |
20% |
$360 million |
| 2027 |
$180 |
20-25% |
$400-$500 million |
Note: Prices and sales are estimates; actual figures depend on market adoption, payer negotiations, and competitive dynamics.
Key Takeaways
- NDC 75907-0072 (levomilnacipran ER) is a niche SNRI with moderate sales volume.
- Its pricing is stable pre-generic entry, with expectations of significant discounts post-generic competition.
- Market growth relies on increased recognition and potential label expansions.
- Competition from established SNRI agents limits premium pricing potential.
- Future sales depend heavily on patent timelines, regulatory developments, and payer policies.
FAQs
1. When will generic versions of levomilnacipran likely enter the market?
Expected in late 2023 to early 2024, once patent exclusivity expires.
2. How will generic entry affect the drug’s price?
Prices could decrease by approximately 50% or more, significantly impacting gross margins.
3. What factors could boost levomilnacipran’s market share?
Label expansions, new indications, insurance coverage improvements, and dosing convenience.
4. What are the primary competitors?
Venlafaxine, duloxetine, desvenlafaxine, and other SNRI agents.
5. Are there any ongoing regulatory studies?
Yes, post-market studies are ongoing for safety and efficacy, with some potential for label updates.
References
- IQVIA (2022). Prescription Drug Sales and Market Shares.
- EvaluatePharma (2022). Global Sales Data.
- FDA (2019). Approved Drug Label for Levomilnacipran.
- U.S. Patent Office (2022). Patent Status for Levomilnacipran Extensions.
